CE15 - Immunologie, Infectiologie et Inflammation 2020

Autophagy-mediated control of tissue-resident macrophage maintenance and function – AUTOMATE

Submission summary

Tissue-resident macrophages (TMs), including epidermal Langerhans cells (LCs), are long-lived cells able to proliferate. Their ontogeny and adaptation to different organs have been studied in great details, yet their physiological maintenance deserves further investigations. Autophagy, a catabolic process regulated by autophagy-related (Atg) genes, prevents accumulation of harmful cytoplasmic components and mobilizes energetic reserves in long-lived and self-renewing cells. Recently, we found that Atg5-deficient LCs undergo apoptosis as a result of lipid metabolism dysregulation. Here, we propose that autophagy allows TMs to manage lipid stocks and ensure long-term maintenance. We will first validate this in murine and human LCs, then verify whether it holds true for TMs of the lung, liver and lymph nodes. Finally, we will test whether autophagy could permit TMs to adapt to cellular stress and limit inflammation induced by metabolic alterations, irradiation, aging and viral infection. Altogether, our results will introduce a new paradigm on the maintenance of TMs in a broad range of organs under physiological and inflammatory conditions.

Project coordination

Vincent FLACHER (Immunologie Immunopathologie et Chimie Thérapeutique (UPR 3572))

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

Partnership

I2CT Immunologie Immunopathologie et Chimie Thérapeutique (UPR 3572)
UMR ICAN Unité de recherche sur les maladies cardiovasculaires, du métabolisme et de la nutrition
IRM IMMUNO-RHUMATOLOGIE MOLÉCULAIRE (UMR_S 1109)

Help of the ANR 586,872 euros
Beginning and duration of the scientific project: December 2020 - 42 Months

Useful links

Explorez notre base de projets financés

 

 

ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter